Ioannis Iakovou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10852016/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer. European Journal of Endocrinology, 2022, 186, G1-G7.	1.9	11
2	Nuclear medicine therapy of thyroid goiter. , 2022, , .		0
3	Oneâ€year clinical and echocardiographic outcomes of direct implantation of a selfâ€expanding valve. Catheterization and Cardiovascular Interventions, 2021, 98, E403-E411.	0.7	3
4	Vitamin D Deficiency as a Risk Factor for Myocardial Ischemia. Medicina (Lithuania), 2021, 57, 774.	0.8	4
5	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. European Journal of Endocrinology, 2020, 183, G41-G48.	1.9	38
6	A Mobile App for Thyroid Cancer Patients Aiming to Enhance Their Quality of Life: Protocol for a Quasiexperimental Interventional Pilot Study. JMIR Research Protocols, 2020, 9, e13409.	0.5	11
7	The impact of depression and anxiety in prognosis of patients undergoing myocardial perfusion imaging with 99mTc tetrofosmin SPECT for evaluation of possible myocardial ischemia. Nuclear Medicine Review, 2020, 23, 58-62.	0.3	9
8	EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2514-2525.	3.3	99
9	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	1.8	2
10	Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR. JACC: Cardiovascular Interventions, 2019, 12, 767-777.	1.1	41
11	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clinical Research in Cardiology, 2019, 108, 643-650.	1.5	21
12	Tumor Protein p53 (TP53) Gene and Left Main Coronary Artery Disease. Angiology, 2018, 69, 730-735.	0.8	11
13	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	1.4	24
14	Gene Polymorphisms in Cardiovascular Disease and Cancer. Angiology, 2018, 69, 738-739.	0.8	1
15	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	0.8	11
16	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	32
17	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq 2017, 120, 904-910.	1 1 0.7843 0.7	10 10 10
18	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	6.3	537

ΙΟΑΝΝΙS ΙΑΚΟΥΟU

#	Article	IF	CITATIONS
19	Optical coherence tomography for guidance in bifurcation lesion treatment. EuroIntervention, 2010, 6, J99-J106.	1.4	45
20	Is there a higher risk of stent thrombosis in bifurcation lesion or is it related to the technique?. EuroIntervention, 2010, 6, J107-J111.	1.4	10
21	Classification of coronary artery bifurcation lesions and treatments: Time for a consensus!. Catheterization and Cardiovascular Interventions, 2008, 71, 175-183.	0.7	260
22	Thrombosis after stent implantation: how much of a problem is there?. Future Cardiology, 2008, 4, 261-267.	0.5	9
23	Bifurcation lesions. , 2008, , 285-296.		0
24	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush―Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	1.2	228
25	Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. American Heart Journal, 2006, 152, 565-572.	1.2	69
26	Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis. American Journal of Cardiology, 2006, 97, 1182-1187.	0.7	24
27	Impact of Sirolimus-Eluting and Paclitaxel-Eluting Stents on Outcome in Patients With Diabetes Mellitus and Stenting in More Than One Coronary Artery. American Journal of Cardiology, 2006, 98, 362-366.	0.7	43
28	Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantationâ€. European Heart Journal, 2006, 27, 540-546.	1.0	89
29	How to perform optimal directional atherectomy. , 2006, , 127-143.		0
30	Thrombosis after implantation of drug-eluting stents. Hellenic Journal of Cardiology, 2006, 47, 31-8.	0.4	3
31	In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. American Journal of Cardiology, 2005, 95, 757-760.	0.7	59
32	Clinical Outcome Following Aleatory Implantation of Paclitaxel-Eluting or Sirolimus-Eluting Stents in Complex Coronary Lesions. American Journal of Cardiology, 2005, 96, 1663-1668.	0.7	42
33	Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?. Catheterization and Cardiovascular Interventions, 2005, 64, 129-133.	0.7	13
34	Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main. Circulation, 2005, 111, 791-795.	1.6	358
35	Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents. JAMA - Journal of the American Medical Association, 2005, 293, 2126.	3.8	2,769
36	Plaque sealing—a concept waiting for support. International Journal of Cardiovascular Interventions, 2005, 7, 72-74.	0.5	4

ΙΟΑΝΝΙS ΙΑΚΟΥΟU

#	Article	IF	CITATIONS
37	Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. Journal of the American College of Cardiology, 2005, 45, 805-806.	1.2	36
38	Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique. Journal of the American College of Cardiology, 2005, 46, 613-620.	1.2	320
39	Contemporary Stent Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2005, 46, 1446-1455.	1.2	245
40	Two-stent techniques for the treatment of coronary bifurcations with drug-eluting stents. Hellenic Journal of Cardiology, 2005, 46, 188-98.	0.4	1
41	Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. European Heart Journal, 2004, 25, 895-897.	1.0	33
42	Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. American Journal of Cardiology, 2004, 93, 963-968.	0.7	23
43	Creatine kinase-myocardial band isoenzyme elevation after percutaneous coronary interventions using sirolimus-eluting stents. American Journal of Cardiology, 2004, 93, 1397-1401.	0.7	10
44	Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. American Journal of Cardiology, 2004, 94, 351-354.	0.7	18
45	Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. American Journal of Cardiology, 2004, 94, 1297-1300.	0.7	20
46	Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 61, 354-359.	0.7	3
47	Favorable effect of ?-radiation for in-stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheterization and Cardiovascular Interventions, 2004, 62, 303-307.	0.7	2
48	Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. Journal of the American College of Cardiology, 2004, 44, 967-971.	1.2	97
49	A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. Journal of the American College of Cardiology, 2004, 44, 1393-1399.	1.2	1,127
50	Ten Years of Advancements in Interventional Cardiology. Journal of Endovascular Therapy, 2004, 11, II-10-II-18.	0.8	5
51	Ten Years of Advancements in Interventional Cardiology. Journal of Endovascular Therapy, 2004, 11, II-10-II-18.	0.8	1
52	Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. American Journal of Cardiology, 2003, 92, 1171-1176.	0.7	30
53	Increased CK-MB release is a "trade-off―for optimal stent implantation. Journal of the American College of Cardiology, 2003, 42, 1900-1905.	1.2	61
54	Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. Journal of Invasive Cardiology, 2003, 15, 18-22.	0.4	103

#	Article	IF	CITATIONS
55	Update on In-stent Restenosis. Current Interventional Cardiology Reports, 2001, 3, 296-305.	0.4	34

ΙΟΑΝΝΙS ΙΑΚΟΥΟU

1

56 RAI Therapy for Gravesâ \in ^M Hyperthyroidism., 0, , .